NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Historical Holders from Q1 2014 to Q3 2025

Symbol: NBIX on Nasdaq
CUSIP: 64125C109
Type / Class: Equity / Common Stock
Shares outstanding: 99.6M
All holders as of September 30, 2025: Q3 2025
Total 13F shares, excl. options: 96.8M
Holdings value: $13.6B
% of all portfolios: 0.012%
Grand Portfolio weight change: 0%
Number of holders: 630
Number of buys: 328
Number of sells: -267
Average Value change %: 0%
Average buys %: +0.003%
Average sells %: -0.005%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
BlackRock, Inc.	12.1%	$1.27B	12.1M	BlackRock, Inc.	Mar 31, 2025
VANGUARD GROUP INC	10.15%	$1.07B	10.1M	The Vanguard Group	Feb 28, 2025
DODGE & COX	5.6%	$585M	5.53M	Dodge & Cox	Mar 31, 2025
STATE STREET CORP	4.8%	$517M	4.89M	STATE STREET CORPORATION	Dec 31, 2024

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	96.8M	$13.6B	-$270M	66.8M	32.2M	$140.38	630
2025 Q2	98.8M	$12.4B	+$494M	26.8M	36.3M	$125.69	577
2025 Q1	95.4M	$10.6B	+$6.53M	56M	82.7M	$110.60	576
2024 Q4	94.3M	$12.9B	+$277M	36.2M	38.4M	$136.50	590
2024 Q3	92.6M	$10.7B	-$221M	66.6M	71.2M	$115.22	567
2024 Q2	93.7M	$12.9B	+$110M	31.3M	90.8M	$137.67	587
2024 Q1	92.8M	$12.8B	+$62.8M	47.4M	69.7M	$137.92	576
2023 Q4	91.7M	$12.1B	+$37.3M	44.3M	55.4M	$131.76	538
2023 Q3	91.1M	$10.3B	+$10.9M	46.3M	56.7M	$112.50	501
2023 Q2	91.3M	$8.61B	+$32.2M	32.8M	34.5M	$94.30	446
2023 Q1	90.7M	$9.18B	+$66.8M	22.9M	13.5M	$101.22	475
2022 Q4	89.8M	$10.7B	+$105M	3.65M	13.2M	$119.44	520
2022 Q3	90.2M	$9.58B	-$38M	4.41M	19.8M	$106.21	446
2022 Q2	89.5M	$8.72B	-$28M	14.6M	49.3M	$97.48	425
2022 Q1	89.9M	$8.43B	+$138M	65.6M	84.9M	$93.75	414
2021 Q4	89.1M	$7.58B	-$143M	48.4M	41.5M	$85.17	389
2021 Q3	90.2M	$8.65B	-$95.6M	34.8M	59.6M	$95.91	386
2021 Q2	91.3M	$8.88B	-$379M	51.4M	70.1M	$97.32	394
2021 Q1	95M	$9.24B	+$548M	50M	59.3M	$97.25	406
2020 Q4	89.4M	$8.57B	-$28.1M	73.1M	30.3M	$95.85	392
2020 Q3	89.6M	$8.62B	-$169M	86M	37.2M	$96.16	405
2020 Q2	91M	$11.1B	+$58.3M	71.9M	71.3M	$122.00	410
2020 Q1	90.4M	$7.83B	+$141M	47.3M	57.6M	$86.55	358
2019 Q4	88.8M	$9.55B	-$106M	50.9M	88.8M	$107.49	384
2019 Q3	89.6M	$8.08B	+$133M	54.1M	57.8M	$90.11	327
2019 Q2	88.9M	$7.5B	+$405M	44.9M	69.9M	$84.43	302
2019 Q1	88.3M	$7.78B	-$72.3M	63.8M	81.3M	$88.10	328
2018 Q4	89.5M	$6.37B	-$95.1M	48.9M	73.5M	$71.41	321
2018 Q3	88.6M	$10.9B	-$351M	81.8M	57.6M	$122.95	341
2018 Q2	91.9M	$9.03B	+$3.59M	65.7M	65.3M	$98.24	275
2018 Q1	92M	$7.63B	-$147M	53.9M	63.8M	$82.93	265
2017 Q4	93.8M	$7.28B	-$129M	35.4M	29.1M	$77.59	260
2017 Q3	96M	$5.88B	+$104M	23M	37.1M	$61.28	221
2017 Q2	94.9M	$4.36B	+$661M	21M	15.1M	$46.00	222
2017 Q1	85.1M	$3.68B	+$239M	11.9M	11.2M	$43.30	218
2016 Q4	84.4M	$3.27B	-$80.5M	22.7M	18.4M	$38.70	227
2016 Q3	85.7M	$4.34B	+$54.6M	6.27M	25.9M	$50.64	238
2016 Q2	84.8M	$3.86B	-$118M	10.9M	68.3M	$45.45	225
2016 Q1	87.6M	$3.46B	+$139M	12.6M	17.1M	$39.55	209
2015 Q4	83.4M	$4.72B	+$51.3M	18.3M	20.5M	$56.57	216
2015 Q3	82.8M	$3.29B	-$27.2M	17.7M	53M	$39.79	204
2015 Q2	83.2M	$3.97B	-$85.1M	13.7M	48.6M	$47.76	195
2015 Q1	85.2M	$3.38B	+$406M	16.3M	22M	$39.71	172
2014 Q4	75.2M	$1.68B	+$53.1M	48.7M	13.2M	$22.34	132
2014 Q3	73.3M	$1.15B	+$43.8M	16.4M	15.3M	$15.67	132
2014 Q2	70.4M	$1.05B	+$8.07M	5.87M	6.4M	$14.84	125
2014 Q1	69.8M	$1.12B	+$195M	6.46M	7.29M	$16.10	122